Mayo Clinic & Profusa Partner to Advance Oxygen Monitoring Technology
Rochester, Minn. – Mayo Clinic and Profusa, Inc. Have entered a collaboration to advance clinical applications of Profusa’s oxygen monitoring technologies, the companies announced February 12, 2026.
The agreement centers on investigating new product development focused on intra-organ perfusion monitoring, with potential applications in cardiovascular, renal, multi-organ, and orthopedic medicine. The partnership also aims to support the potential commercialization of Profusa’s Lumee™ tissue oxygen sensor in the United States for the treatment of chronic limb-threatening ischemia (CLTI), a condition characterized by severely reduced blood flow to the limbs.
Profusa’s technology, developed over more than a decade with over $100 million in investment, is designed to continuously measure oxygen levels within the body. The Lumee platform is a wearable sensor intended to provide real-time biochemical data directly from tissues. According to Profusa, the collaboration will leverage Mayo Clinic’s clinical expertise and access to investigators to accelerate regulatory approval and commercialization efforts.
“Oxygen is essential for cellular metabolism and tissue repair, with lack of sufficient oxygenation impairing wound healing, increasing risk of infection, and contributing to complications common to surgery, such as leakage and anastomotic structure,” said Michael Kendrick, M.D., Chair of Department of Surgery at Mayo Clinic, in a statement released by Profusa. “Our collaboration gives us the opportunity to leverage their innovative platform to potentially address unmet clinical challenges, including the ability to monitor beyond subcutaneous tissue.”
The collaboration involves a grasp-how agreement and a global licensing agreement, granting Profusa an exclusive license to key patents and related know-how from Mayo Clinic in continuous oxygen measurement and CLTI. Profusa will also pay royalties on net sales, milestone payments tied to development and commercialization achievements, and a portion of any income generated from sublicensing the technology, according to a February 14, 2026 report. The license will remain in effect until the expiration of the last patent or 15 years after the first commercial sale of a licensed product.
Mayo Clinic has a financial interest in the technology being developed through the collaboration, with any revenue received being reinvested into its not-for-profit mission supporting patient care, medical education, and research.